RECCE PHARMACEUTICALS LTD(RCE.AU)

0.66+0.01+1.54%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- BUZZ-Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate
  Reuters · 01-14
  BUZZ-Australia's Recce Pharmaceutical hits over 2-yr high on $3.5 million R&D tax rebate
- Tencent Cloud Announces Strategic Partnership with Thailand's Leading Digital Asset Exchange Bitkub
  prnewswire · 2025-12-17
  Tencent Cloud Announces Strategic Partnership with Thailand's Leading Digital Asset Exchange Bitkub
- BRIEF-Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85M
  Reuters · 2025-12-16
  BRIEF-Recce Pharmaceuticals Awarded Ausindustry Advanced Overseas Finding For Up To A$85M
- BUZZ-Australia's Recce Pharmaceuticals hits 1-week high on $56.5 mln R&D boost
  Reuters · 2025-12-16
  BUZZ-Australia's Recce Pharmaceuticals hits 1-week high on $56.5 mln R&D boost
- Recce Pharmaceuticals Ltd - Awarded Ausindustry Advanced Overseas (R&D) Finding for up to a$85M
  THOMSON REUTERS · 2025-12-16
  Recce Pharmaceuticals Ltd - Awarded Ausindustry Advanced Overseas (R&D) Finding for up to a$85M
- Insiders Of Recce Pharmaceuticals Are Up 73% On Their AU$6.19m Purchase
  Simply Wall St. · 2025-11-30
  Insiders Of Recce Pharmaceuticals Are Up 73% On Their AU$6.19m Purchase
- Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%
  MT Newswires Live · 2025-11-27
  Recce Pharmaceuticals Secures Family 4 Patent for Anti-Infectives in Hong Kong, Shares Jump 6%
- Recce Pharmaceuticals Says Hospital/Ventilator-Acquired Pneumonia Study in Mice Shows Antibacterial Activity of R327 Therapy Candidate
  MT Newswires Live · 2025-11-26
  Recce Pharmaceuticals Says Hospital/Ventilator-Acquired Pneumonia Study in Mice Shows Antibacterial Activity of R327 Therapy Candidate
- Recce Receives 'First Strike' Against Remuneration Report; Shares Up 3%
  MT Newswires Live · 2025-11-05
  Recce Receives 'First Strike' Against Remuneration Report; Shares Up 3%
- Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections
  Small Caps · 2025-09-25
  Recce Pharmaceuticals Commences Phase 3 Trial of Topical Gel for Diabetic Foot Infections
- BRIEF-Recce Pharmaceuticals Reports FY Net Loss Attributable A$21.4 Million
  Reuters · 2025-08-29
  BRIEF-Recce Pharmaceuticals Reports FY Net Loss Attributable A$21.4 Million
- Recce Pharmaceuticals Ltd - FY Net Loss Attributable a$21.4 Mln
  THOMSON REUTERS · 2025-08-29
  Recce Pharmaceuticals Ltd - FY Net Loss Attributable a$21.4 Mln
- Recce Pharmaceuticals Says Topical Gel Achieves Significant Reduction in Bacterial Load for Antibiotic-Resistant Pathogens
  MT Newswires Live · 2025-08-12
  Recce Pharmaceuticals Says Topical Gel Achieves Significant Reduction in Bacterial Load for Antibiotic-Resistant Pathogens
Company Profile
Company Name
RECCE PHARMACEUTICALS LTD
Market
ASX
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.recce.com.au
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of antibiotics in Australia and the United States. Its lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

1D
5D
Day
Week
Month

Loading ...

High

0.67

Open

0.65

Volume%

0.62

Low

0.65

T/O Rate

0.04%

To The Moon

RECCE PHARMACEUTICALS LTD(RCE.AU)

Company Profile

Most Discussed